The Cardiovascular Research Foundation (CRF®) has unveiled a groundbreaking lineup of late-breaking clinical trials and scientific presentations for TCT® 2025, the apex annual symposium in interventional cardiovascular medicine. Scheduled from October 25 to 28 at San Francisco’s Moscone Center, this global gathering of leading cardiologists, innovators, and researchers will showcase pivotal advancements set to reshape cardiovascular treatment paradigms worldwide. Now in its fourth decade, TCT continues to serve as a beacon for cutting-edge cardiovascular science, merging rigorous research with transformative clinical applications.
Over the years, TCT® has cemented its reputation as the foremost venue for unveiling data that profoundly influence patient care and therapeutic guidelines in cardiovascular medicine. The symposium’s late-breaking clinical trials sessions remain among the most eagerly anticipated components, offering the first presentation of novel device technologies, pharmaceutical agents, and interventional techniques designed to improve outcomes in heart and vascular disease. In 2025, the program includes 28 such trials that underscore recent innovations targeting minimally invasive procedures, drug delivery systems, and diagnostic technologies.
Among the highlights slated for Sunday, October 26, are the one-year results of the SELUTION DeNovo trial. This randomized study compares percutaneous coronary intervention (PCI) using a sirolimus-eluting balloon combined with provisional stenting against the conventional approach of systematic drug-eluting stent (DES) implantation for de novo coronary lesions. The nuanced understanding of vascular healing and restenosis suppression offered by sirolimus drug delivery could redefine interventional strategies in complex coronary disease.
Another significant focus on this day is the randomized comparison between intravascular lithotripsy and cutting balloon angioplasty for calcified coronary artery disease, as demonstrated in the Short-CUT and VICTORY trials. These studies evaluate the mechanobiological impact and procedural efficacy of lithotripsy—a novel modality employing sonic pressure waves to fracture calcific plaques—contrasted with conventional mechanical plaque modification techniques. The findings could optimize lesion preparation protocols and improve stent expansion in heavily calcified vessels, a notorious challenge in interventional cardiology.
The day’s scientific agenda further includes analyses from the STORM-PE trial on mechanical thrombectomy combined with anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. This multicenter investigation assesses whether adjunctive thrombectomy enhances clot clearance and improves hemodynamic parameters without increasing bleeding risk, an important step toward refining pulmonary embolism management.
Monday, October 27, delves deeply into valvular heart disease and long-term device outcomes. The PREVUE-VALVE study presents critical epidemiological data defining the prevalence of valvular disease among the older American population, drawing attention to the rising clinical burden and the need for optimized screening and management pathways. Complementarily, the seven-year clinical and echocardiographic follow-up of the PARTNER 3 low-risk randomized trial provides invaluable insights into the durability and safety profile of transcatheter aortic valve replacement (TAVR) in a broader demographic.
Technological innovation in mitral valve interventions takes center stage with presentations on the Tendyne Transcatheter Mitral Valve System and the SAPIEN M3 balloon-expandable valve, both examining outcomes in complex mitral annular calcification and transseptal mitral valve replacement, respectively. These studies exemplify the ongoing evolution of structural heart disease therapy toward less invasive, catheter-based solutions with durable, physiological restoration of valve function.
Further enriching the program is the INFINITY-SWEDEHEART randomized trial, which contrasts the Bioadaptor device—a novel bioresorbable scaffold—against contemporary drug-eluting stents in coronary artery disease. In parallel, the OCVC-BIF study interrogates the comparative utility of drug-coated versus conventional balloons for side branch treatment in bifurcation lesions, a niche yet highly relevant clinical scenario prone to restenosis and procedural complexity.
Tuesday, October 28, features pivotal data addressing revascularization strategies in surgical and STEMI populations. The PROCTOR trial offers a landmark comparison of PCI in native coronary arteries versus saphenous vein grafts in post-coronary artery bypass surgery patients, shedding light on procedural success rates, graft patency, and long-term clinical endpoints. The adjunctive use of low-dose intracoronary recombinant tissue plasminogen activator during primary PCI in STEMI patients with large thrombus burdens, assessed in a randomized double-blind trial, could further advance reperfusion strategies and mitigate microvascular obstruction.
The agenda also includes innovative approaches leveraging advanced imaging and physiological assessments to guide revascularization. For instance, the comparison of instantaneous wave-free ratio (iFR) versus cardiac magnetic resonance imaging (MRI) guided strategies for treating non-culprit lesions in ST-elevation myocardial infarction patients represents a cutting-edge attempt to individualize intervention based on functional and tissue characterization markers. Moreover, the PROMISE trial’s stratified treatment approach for myocardial infarction with non-obstructive coronary arteries (MINOCA) addresses an under-recognized patient subset, highlighting the challenge of tailored therapy in heterogeneous pathophysiologies.
Device innovation rigor continues with head-to-head randomized trials such as TUXEDO-2, comparing Supraflex Cruz with Xience drug-eluting stents in diabetic patients with multivessel coronary disease. The 3-year results of the iCABG trial offer new perspectives on the role of angiography and physiology in guiding coronary artery bypass grafting. Additionally, the TALENT multicenter study pits Supraflex CruzTM stents against SYNERGYTM, pushing the frontier in scaffold technology and polymer design.
Complementing the interventional studies, a prospective trial evaluating hemodynamic support devices—novel percutaneous ventricular assist devices (pVADs) versus intra-aortic balloon pumps (IABP)—will provide insightful data on circulatory support strategies for high-risk PCI cases. Meanwhile, the AI-enabled ECG interpretation trial in STEMI patients from a multicenter U.S. registry exemplifies the transformative interface of artificial intelligence with acute cardiovascular care, promising earlier detection and swift therapeutic escalation.
Finally, the INVEST CTO single-arm study explores planned investment procedures in high-risk chronic total occlusions, an area with significant procedural complexity and risk where scaffold scaffolding or lesion preparation strategies may vastly improve success rates.
The upcoming TCT® 2025 promises an unparalleled confluence of scientific breakthroughs and clinical insights, reinforcing its standing as a preeminent forum that equips cardiovascular specialists with the latest evidence to enhance patient survival, quality of life, and procedural safety. Media engagement and open dissemination of these results will expedite their translation from bench to bedside, ultimately shaping the future landscape of cardiovascular therapeutics.
Subject of Research: Late-breaking clinical trials and innovations in interventional cardiovascular medicine presented at TCT® 2025.
Article Title: Revolutionizing Cardiovascular Care: A Preview of Late-Breaking Trials and Innovations at TCT® 2025
News Publication Date: August 27, 2025
Web References:
https://www.tctconference.com/late-breaking-research
https://www.tctconference.com/press-registration
https://x.com/crfheart
http://www.crf.org
http://www.tctconference.com
Keywords: Interventional cardiovascular medicine, percutaneous coronary intervention, drug-eluting stents, intravascular lithotripsy, pulmonary embolism, valvular heart disease, transcatheter mitral valve replacement, bioresorbable scaffolds, coronary artery bypass grafting, STEMI, myocardial infarction, drug-coated balloons, artificial intelligence in cardiology
